All Posts
  • Press Releases
1 min read

Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

On this page

Share

On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026

TRX319 is an allogeneic CAR-Tr1 Treg cell therapy designed to pair targeted B-cell control with active anti-inflammatory signaling and pathogenic T-cell modulation in a CNS-penetrant package

Related Articles

Explore posts connected to this topic

View Resources

Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit

San Diego, CA, and Bergisch Gladbach, Germany – September 15, 2026 – Tr1X, Inc. and Miltenyi Biotec today announced that...

  • Press Releases

CIRM approves more than $60 million to support clinical and preclinical development awards

South San Francisco, CA, June 25, 2026 – The California

  • Press Releases

Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease

  • Press Releases

San Diego, CA, and Bergisch Gladbach, Germany – September 15,

  • Press Releases

South San Francisco, CA, June 25, 2026 – The California

  • Press Releases

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease

  • Press Releases